Progenics’ Azedra gets FDA approval for rare adrenal gland tumors

07:13 EDT 1 Aug 2018 | Pharmaceutical Business Review

The approval is for the intravenous use of the Azedra injection in patients whose adrenal gland tumors are unresectable and have spread beyond the original tumor site and

The post Progenics’ Azedra gets FDA approval for rare adrenal gland tumors appeared first on Pharma Business review.

Original Article: Progenics’ Azedra gets FDA approval for rare adrenal gland tumors

More From BioPortfolio on "Progenics’ Azedra gets FDA approval for rare adrenal gland tumors"